NASDAQ:ARVN Arvinas Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arvinas Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.89 -0.66 (-2.69 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$23.49Now: $23.89▼$24.8350-Day Range$24.15MA: $26.39▼$30.6752-Week Range$15.19Now: $23.89▼$61.57Volume437,056 shsAverage Volume452,932 shsMarket Capitalization$937.40 millionP/E RatioN/ADividend YieldN/ABeta1.45 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.10, Arvinas has a forecasted upside of 139.0% from its current price of $23.89.Amount of Analyst CoverageArvinas has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesArvinas has received 85 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArvinas has received 99 “underperform” votes. (Add your “underperform” vote.)Community SentimentArvinas has received 53.80% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote “Outperform” if you believe ARVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,490.00 in company stock.Percentage Held by InsidersOnly 10.99% of the stock of Arvinas is held by insiders.Percentage Held by Institutions92.51% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($2.57) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARVN Previous Symbol CUSIPN/A CIKN/A Webwww.arvinas.com Phone203-535-1456Debt Debt-to-Equity Ratio0.01 Current Ratio7.40 Quick Ratio7.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.98 million Price / Sales21.81 Cash FlowN/A Price / Cash FlowN/A Book Value$6.72 per share Price / Book3.56Profitability EPS (Most Recent Fiscal Year)($2.13) Net Income$-70,290,000.00 Net Margins-182.59% Return on Equity-31.68% Return on Assets-23.12%Miscellaneous Employees83 Outstanding Shares39,238,000Market Cap$937.40 million Next Earnings Date11/2/2020 (Estimated) OptionableNot Optionable $23.89 -0.66 (-2.69 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ARVN News and Ratings via Email Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Arvinas (NASDAQ:ARVN) Frequently Asked Questions How has Arvinas' stock been impacted by Coronavirus? Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has decreased by 45.8% and is now trading at $23.89. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Arvinas? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas. When is Arvinas' next earnings date? Arvinas is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Arvinas. How were Arvinas' earnings last quarter? Arvinas Inc (NASDAQ:ARVN) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.65) EPS for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.06. The business earned $5.75 million during the quarter, compared to analysts' expectations of $5.73 million. Arvinas had a negative return on equity of 31.68% and a negative net margin of 182.59%. View Arvinas' earnings history. What price target have analysts set for ARVN? 11 equities research analysts have issued twelve-month target prices for Arvinas' stock. Their forecasts range from $38.00 to $75.00. On average, they expect Arvinas' share price to reach $57.10 in the next year. This suggests a possible upside of 139.0% from the stock's current price. View analysts' price targets for Arvinas. Who are some of Arvinas' key competitors? Some companies that are related to Arvinas include Legend Biotech (LEGN), Biohaven Pharmaceutical (BHVN), HYPERA S A/S (HYPMY), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Turning Point Therapeutics (TPTX), Reata Pharmaceuticals (RETA), Insmed (INSM), Principia Biopharma (PRNB), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH) and TG Therapeutics (TGTX). View all competitors. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Crispr Therapeutics (CRSP), Energy Transfer LP Unit (ET), Nabriva Therapeutics (nbrv), NVIDIA (NVDA), Opko Health (OPK), Enphase Energy (ENPH) and G1 Therapeutics (GTHX). Who are Arvinas' key executives? Arvinas' management team includes the following people: Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)Dr. Ian Taylor, Chief Scientific Officer (Age 56)Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardDr. Andrew Crew, Chief Technology Officer (Age 54) When did Arvinas IPO? (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. What is Arvinas' stock symbol? Arvinas trades on the NASDAQ under the ticker symbol "ARVN." Who are Arvinas' major shareholders? Arvinas' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.75%), Bellevue Group AG (4.03%), Gilder Gagnon Howe & Co. LLC (3.66%), Vanguard Group Inc. (2.80%), Avidity Partners Management LP (2.74%) and Deerfield Management Company L.P. Series C (2.57%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View institutional ownership trends for Arvinas. Which institutional investors are selling Arvinas stock? ARVN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Hillhouse Capital Advisors LTD., Deerfield Management Company L.P. Series C, RTW Investments LP, Federated Hermes Inc., Gilder Gagnon Howe & Co. LLC, Holocene Advisors LP, and ArrowMark Colorado Holdings LLC. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy. View insider buying and selling activity for Arvinas. Which institutional investors are buying Arvinas stock? ARVN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Avidity Partners Management LP, Bellevue Group AG, Two Sigma Advisers LP, Vanguard Group Inc., Man Group plc, Alyeska Investment Group L.P., and Candriam Luxembourg S.C.A.. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon. View insider buying and selling activity for Arvinas. How do I buy shares of Arvinas? Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arvinas' stock price today? One share of ARVN stock can currently be purchased for approximately $23.89. How big of a company is Arvinas? Arvinas has a market capitalization of $937.40 million and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe. What is Arvinas' official website? The official website for Arvinas is www.arvinas.com. How can I contact Arvinas? Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
